TNFRSF11A and non-small cell lung carcinoma: Interestingly, some retrospective studies on non-small-cell lung cancer (NSCLC) have shown that denosumab may improve the OS [175,176] due to the direct blocking of RANKL in NSCLC tumors, in which RANK and RANKL expression was identified.